IL-1 blocking agents (particularly anakinra) are used for the treatment of RA, and some studies have shown the efficacy of IL-1 receptor antagonism in patients with RA and comorbid T2D [172]. The gene discussed is IL1A; the disease is rheumatoid arthritis.